8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2008

SCHERING–PLOUGH CORPORATION

(Exact Name of Registrant as Specified in its Charter)

New Jersey	1-6571	22-1918501
(State or Other Jurisdiction of	(Commission File Number)	(IRS Employer
Incorporation)		Identification Number)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Schering-Plough Corporation from time to time issues Frequently Asked Questions and Answers (FAQs) that are believed to be of interest to investors. The most recent FAQ, dated August 18, 2008, is furnished as Exhibit 99.1 to this 8-K and is posted on the Schering-Plough Website at www.schering-plough.com under “Investor Relations/Investor FAQs.”

Schering-Plough undertakes no obligation to update the FAQs and readers should take note of the date of information when referring to the FAQs or other historical information available on the website.

Page 2

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 August 18, 2008 Frequently Asked Questions and Answers

Page 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By:	/s/ Steven H. Koehler
Steven H. Koehler
Vice President and Controller

Date: August 18, 2008

Page 4

Exhibit Index

Exhibit
Number	Description
99.1	August 18, 2008 Frequently Asked Questions and Answers

Page 5

EX-99.1

Exhibit 99.1

August 18, 2008 — Frequently Asked Questions and Answers – (FAQs)

From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a recent FAQ.

Q	What are the IMS prescription volumes for VYTORIN and ZETIA?
A	U.S. Total Prescription Volume (000’s)

	January		February		March		April		May		June		July
	2008		2008		2008		2008		2008		2008		2008
Cholesterol Management Market		20,402		18,941		19,687		19,543		19,804		19,398		20,294
Total Merck/Schering-Plough Franchise		3,205		2,773		2,803		2,492		2,463		2,352		2,378
VYTORIN		1,839		1,597		1,610		1,420		1,404		1,330		1,339
ZETIA		1,366		1,176		1,193		1,072		1,060		1,022		1,039

Source: IMS’ National Prescription Audit Plus (NPA+) as of August 13, 2008, which includes routine refinements by IMS to previously published data.

DISCLOSURE NOTICE: The information in the frequently asked questions included in this FAQ, and in other written and oral statements about Schering-Plough and its business made by Schering-Plough or its officers from time to time, includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to prescription trends for VYTORIN and ZETIA.

Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward-looking statements, including market forces (such as customer buying patterns); economic factors; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the timing and outcomes of the regulatory process; and prescriber, patient and media reaction to data obtained from post-marketing clinical trials, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II, Item 1A. “Risk Factors” in Schering-Plough’s 10-Q for the quarterly period ended June 30, 2008, filed August 1, 2008.

Page 6